Valeritas Holdings Inc. (fka VLRXQ)

[airahim]

I think this is the peak. News is enough to push it much higher. Similar news came out previously

[crudeoil24]

May pop that 3.35 ceiling @ opening bell.

[PickPocketer]

NEWS @ 7:00 AM ET! Here we gooooooo!

[stock1ace1]

Breaking $2.65 nice news out

[stock1ace1]

2.40$ now !

[stock1ace1]

Vlrx 1.90$ news out gapping p/m

[ClayTrader]

* * $VLRX Video Chart 05-18-18 * *

Link to Video - click here to watch the technical chart video

[silkyballer]

Squeezing.... in at 1.40

[stock1ace1]

VlRX 1.80$s News Out ! Gapping p/m

[LiveLife]

Last 2 days of higher volume with rebound from $1.50.

I think we test $2 next -
https://stocktradingmodel.wordpress.com/

[LiveLife]

Edited transcript of conference call - https://finance.yahoo.com/news/edited-transcript-vlrx-earnings-conference-215455137.html

[LiveLife]

Clinical benefit news of VLRX Wearable Insulin Delivery Device Sustained Over Time in Patients with Diabetes - https://globenewswire.com/news-release/2018/05/14/1501564/0/en/Valeritas-V-Go-Wearable-Insulin-Delivery-Device-Results-in-Clinical-Benefits-Sustained-Over-Time-in-Patients-with-Diabetes.html

"BRIDGEWATER, N.J., May 14, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today the publication last week of a manuscript titled 'Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: a Retrospective Analysis' in Advances in Therapy, an international, peer-reviewed journal. The 14-month analysis showed that patients with diabetes benefited from significant and sustained reductions in A1C compared to baseline over time with V-Go use.

'Diabetes is a chronic progressive disease and managing multiple insulin injections can be a constant challenge for patients with diabetes when a basal-bolus insulin regimen is required to reach treatment goals,' said Dr. David Sutton, lead author and Co-Founder, Northeast Florida Endocrine and Diabetes Associates, LLC in Jacksonville, Florida, US. “We are encouraged to see the clinical benefits of V-Go are sustained over time.”

The current study demonstrated V-Go use was associated with improved A1C which was sustained for over a year in 103 patients with diabetes in a real-world setting. Reductions in A1C with V-Go ranged from 1.3 – 1.7% over the course of the study. At baseline, 33% of patients used two or more concomitant medications and, by 14 months this was reduced by more than half to 15% of patients. Therefore, the improvements in A1C seen in the study were not attributable to changes in concomitant non-insulin glucose lowering medications. Further, improvements in A1C were achieved using less insulin. Patients prescribed basal-bolus regimens with conventional insulin delivery at baseline observed a reduction in insulin of nearly 30% after switching to V-Go.

'V-Go provides patients a simpler and more convenient alternative to having to take multiple daily shots in order to deliver basal-bolus insulin and we are pleased to see additional evidence published supporting the benefits of V-Go for insulin delivery in patients with diabetes.' said John Timberlake, President and Chief Executive Officer of Valeritas."

https://stocktradingmodel.wordpress.com/

[Awl416]

Ouch

[halpern6]

so much for the $3 open..great buying opp...eom

[halpern6]

Here I thought your prediction was a stretch...ended up being conservative. After hours seems to show an open @ 3 or above very likely....

[ClayTrader]

* * $VLRX Video Chart 04-23-18 * *

Link to Video - click here to watch the technical chart video

[stock1ace1]

Volume

[stock1ace1]

4s hit $$$

[fact4]

Hey clay can you do another video but this time with the resistance levels

[tripleDz]

$3.50 Monday and 4.00 by Wednesday—imo

[stock1ace1]

$3.12 A/h

[ClayTrader]

* * $VLRX Video Chart 04-20-18 * *

Link to Video - click here to watch the technical chart video

[stock1ace1]

Going up

[akamaii]

Looks like another fail short for the clay clique

[ClayTrader]

* * $VLRX Video Chart 04-17-18 * *

Link to Video - click here to watch the technical chart video

[willlbone]

Actually sold vtvt yesterday for a small gain. Not my week.

[europtiger]

Unlucky buddy

Try some vtvt Maybe Could be a couple day Runner

[willlbone]

Had bids yesterday. Missed buy a dime.

[europtiger]

Good run today...

[willlbone]

So 50% drop in a month. Bid one dollar.

[stock1ace1]

VLRX $3.35 ******

[akamaii]

I have my own proprietary system if you'd like you can pay for my system it failed so I sold

[CIMA7]

When? Lol...

[akamaii]

Sold loss here

[akamaii]

Bull flag on this one going way higher

[stocktrademan]

VLRX bullish 5.85

just watching this chart to see what it does

normal chart




log chart

[Renee]

VLRX moved to the Nasdaq from the OTC.:

http://otce.finra.org/DLAdditions

[Renee]

VLRX one for 8 reverse split:

http://otce.finra.org/DLSymbolNameChanges

[nodummy]

Considering that Michael Forster first took this Issuer public as Cleaner Yoga Mat Inc registered 1,000,004 shares to be free trading through the S-1 and subsequent 4.0486:1 forward split, the reverse split probably should have happened a long time ago.

Valeritas Holdings Inc never should have acquired a shell created by Michael Forster, and after they did they should have wiped him and his S-1 registered free trading stock out immediately after the acquisition closed.

But it looks like the reverse split is primarily to try to get the ticker uplisted to the NASDAQ.

[Big Brother]

Reverse split coming....did this really need that..??

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11928468

BRIDGEWATER, New Jersey, March 13, 2017 — Valeritas Holdings, Inc. (OTCQB: VLRX) today announced that effective at 9:00 a.m., EDT, on March 15, 2017, the Company will effect an eight-for-one reverse stock split of its outstanding common stock. The authority to implement a reverse stock split was approved by the Company’s stockholders at the Special Meeting of Stockholders held on March 8, 2017, and the Company’s Board of Directors subsequently adopted the reverse stock split. Upon the effectiveness of the reverse stock split, every eight shares of issued and outstanding common stock as of the close of business on March 14, 2017 will be combined into one issued and outstanding share of common stock, with no change in par value per share. The Company’s common stock will open for trading on the OTCQB on March 15, 2017 on a post-split basis.
The reverse stock split is primarily intended to bring the Company into compliance with the minimum average closing share price requirement for its potential up-listing onto the Nasdaq Capital Market. The Company’s common stock will continue to trade under the symbol “VLRX” but will have a new CUSIP number (91914N 202).
The reverse stock split will reduce the number of shares of the Company’s outstanding common stock from approximately 13.1 million shares to approximately 1.6 million shares. No fractional shares will be issued as a result of the reverse stock split. Any fractional shares that would result from the reverse stock split will be settled in cash. Shareholders holding share certificates will receive information from West Coast Stock Transfer, the Company’s transfer agent, regarding the process for exchanging their shares of common stock.
Shareholders with questions may contact our transfer agent at West Coast Stock Transfer by calling 619.664.4780.
Additional information about the reverse stock split can be found in the Company’s proxy statement filed with the Securities and Exchange Commission on February 15, 2017, a copy of which is available at www.sec.gov .
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go ® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides
discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com .
Forward Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go ® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the Securities and Exchange Commission available at www.sec.gov .
Investor Contacts:
Nick Laudico / Robert Flamm, Ph.D.
The Ruth Group
[phone] / 7017
[e-mail]
Or
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
[e-mail]
Media Contact:
Kirsten Thomas
The Ruth Group
[phone]
[e-mail]

[FIERCE]

$VLRX chart

[FIERCE]

$VLRX has big potential with a low OS and very nice revenue.

Look for charts to turn even further bullish

[FIERCE]

$VLRX is a great company to go long on imo.

Very much under the radar

The OS from last 10q is still only 12mil

[FIERCE]

$VLRX $20,000,000 annual revenues Zachs research report says $12 per share!

http://s1.q4cdn.com/460208960/files/News/2016/November-23-2015_VLRX_Marckx.pdf?utm_content=buffer5cb76&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

https://twitter.com/fiercestocks/status/805777900708433923

[Renee]

CYGMD: effective May 27,2016 CYGMD will change to VLRX:

http://otce.finra.org/DLSymbolNameChanges

[Renee]

Cleaner Yoga Mat Inc. changed to Valeritas Holdings, Inc. and a 4.0483 for one forward split:

http://otce.finra.org/DLSymbolNameChanges

[ChampFox]

At what level would you buy?

[MONEY MAID]

I am the first!
I'm all for cleaner yoga which is usually soooo dirty.